ArticleArthritis research & therapy2009
Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort.
Article in Arthritis research & therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 61 citations in OpenAlex.
- Recent Advances in Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease: Clinical Relevance and Therapeutic Perspectives.Life (Basel, Switzerland) · 2026Review
- Predictive Value of Classical and Emerging Autoantibodies for Cardiac Dysfunction in Systemic Sclerosis: Systematic Review.Journal of clinical medicine · 2025Review
- ECM formation and degradation during fibrosis, repair, and regeneration.npj metabolic health and disease · 2025Review
- Distinct clinical trajectories of gastrointestinal progression among patients with systemic sclerosis.Rheumatology (Oxford, England) · 2025Article
- Levels of anti-topoisomerase I antibody correlated with short onset of cardiopulmonary involvement in Thai systemic sclerosis patients.Scientific reports · 2024Article
- Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers.Clinical reviews in allergy & immunology · 2023Article
- Autoantibodies and Clinical Correlations in Polish Systemic Sclerosis Patients: A Cross-Sectional Study.Journal of clinical medicine · 2023Article
- The mosaic of autoimmunity - Finally discussing in person. The 13Autoimmunity reviews · 2022Article
- The Effect of Anti-Scl-70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis.ACR open rheumatology · 2022Article
- Can Antinuclear Antibodies Have a Pathogenic Role in Systemic Sclerosis?Frontiers in immunology · 2022Review
- Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2020Article
- Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment.Seminars in immunopathology · 2015Review
- Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients.Rheumatology international · 2013Article
- Detection of autoantibodies in a point-of-care rheumatology setting.Auto- immunity highlights · 2013Review
- N-TproBNP as biomarker in systemic sclerosis.Clinical reviews in allergy & immunology · 2012Review
- Biomarkers in the management of scleroderma: an update.Current rheumatology reports · 2011Review
- Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features.Arthritis research & therapy · 2011Article
- Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.Arthritis research & therapy · 2009Article
- Plasma endogenous enkephalin levels in early systemic sclerosis: clinical and laboratory associations.Clinical and experimental rheumatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn the present study, the detection of anti-topoisomerase I (anti-topo I) autoantibodies was evaluated for diagnosis and risk assessment of systemic sclerosis (SSc) patients in a well characterized large monocentric cohort.
methodsSera from patients with SSc (diffuse n = 96, limited n = 113), from patients with overlap syndromes (n = 51), from patients with other diseases associated with SSc (n = 20), as well as from disease controls (n = 487) were analysed for the presence of anti-topo I antibodies by line immunoblot assay and ELISA. Assessment of organ manifestations was performed as proposed by the European Scleroderma Trial and Research network.
resultsThe applied test systems for the detection of anti-topo I antibodies revealed a diagnostic sensitivity for SSc of approximately 24% and a diagnostic specificity of at least 99.6%. The sensitivity to identify patients with diffuse SSc amounted to 60%. Patients with anti-topo I antibodies showed a higher burden of skin and lung fibrosis, contractures, electrocardiogram changes, as well as digital ulcers and had more active disease than antibody-negative patients. Signal strengths correlated only weakly with disease activity, with modified Rodnan skin score, with predicted forced vital capacity, and with predicted diffusion capacity levels (P = 0.01, rho = 0.234, rho = 0.413, rho = -0.215, rho = -0.219). High signal intensities were associated with an increased mortality in diffuse SSc patients (P = 0.003).
conclusionsDiagnosis and risk assessment of SSc patients can be supported by the detection of anti-topo I antibodies. Signal intensities as obtained by line immunoblot assay or ELISA can be used as a surrogate marker for fibrosis, active disease and worse prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.